Cost study of the clinical management of prostate cancer in France: Results on the basis of population-based data

European Journal of Health Economics

Volumn 12, Issue 4, 2011, Pages 363-371

  Molinier, Laurent ^a,b   Castelli, Christel ^c,d   Bauvin, Eric ^a,e   Rebillard, Xavier ^f   Soulié, Michel ^a,b   Daurès, Jean Pierre ^c,d   Grosclaude, Pascale ^a,g  

^a INSERM   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c UNIV MONTPELLIER   (France)

^d NÎMES UNIVERSITY HOSPITAL   (France)

^e Facultéde Médecine Réseau Régional de Cancérologie ^*  (France)

^f Clinique Beau Soleil   (France)

^g Registre des Cancers du Tarn   (France)

Author keywords

Cost study; Management; Population based data; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; FRANCE; HEALTH CARE COST; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; TRAVEL; WATCHFUL WAITING; CLASSIFICATION; COST; ECONOMICS; HEALTH SURVEY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; STATISTICS; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; COSTS AND COST ANALYSIS; FOLLOW-UP STUDIES; FRANCE; HEALTH CARE COSTS; HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 80052604630     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0250-6     Document Type: Article

References (42)

1. Ruchlin, H.S., Pellissier, J.M.: An economic overview of prostate carcinoma. Cancer 92, 2796-2810 (2001) (Pubitemid 33091916)
2. Parkin, D.M., Bray, F., Ferlay, J., Pisani, P.: Global cancer statistics, 2002. CA. Cancer J. Clin. 55, 74-108 (2005)
3. Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., Boyle, P.: Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592 (2007) (Pubitemid 46359643)
4. Institut de Veille Sanitaire: Estimation cancer, Incidence - Mortalité, 1980-2005. http://www.invs.sante.fr/surveillance/ cancers/estimations-cancers (2009). Accessed 23 January 2009
5. Aus, G., Abbou, C.C., Bolla, M., Heidenreich, A., Schmid, H.P., van Poppel, H., Wolff, J., Zattoni, F.: EAU guidelines on prostate cancer. Eur. Urol. 48, 546-551 (2005) (Pubitemid 41278578)
6. Samant, R.S., Dunscombe, P.B., Roberts, G.H.: A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urol. Oncol. 21, 171-177 (2003) (Pubitemid 36723703)
7. Sennfält, K., Carlsson, P., Thorfinn, J., Frisk, J., Henriksson, M., Varenhorst, E.: Technological changes in the management of prostate cancer result in increased healthcare costs. A retrospective study in a defined Swedish population. Scand. J. Urol. Nephrol. 37, 226-231 (2003) (Pubitemid 36798047)
8. Grover, S.A., Zowall, H., Coupal, L., Krahn, M.D.: Prostate cancer: 12. The economic burden. Can. Med. Assoc. J. 160, 685-690 (1999) (Pubitemid 29149800)
9. Grover, S.A., Coupal, L., Zowall, H., Rajan, R., Trachtenberg, J., Elhilali, M., Chetner, M., Goldenberg, L.: The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can. Med. Assoc. J. 162, 987-992 (2000) (Pubitemid 30207497)
10. Molinier, L., Bauvin, E., Combescure, C., Castelli, C., Rebillard, X., Soulié, M., Daurès, J.P., Grosclaude, P.: Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health 11, 878-885 (2008)
11. Soulié, M., Grosclaude, P., Villers, A., Menegoz, F., Schaffer, P., Mace-Lesec'h, J., Molinier, L., Sauvage-Machelard, M.: A population- based study on management of prostate cancer in four regions of France. Prostate Cancer Prostatic Dis. 4, 154-160 (2001) (Pubitemid 32923229)
12. Bauvin, E., Molinier, L., Dervaux, B., Soulié, M., Latorzeff, I., Bachaud, J.M., Villers, A., Elias, A., Grosclaude, P.: Cost and efficacy of treatment strategies in localized prostatic cancer: feasibility study in the general population. Prog. Urol. 13, 618-623 (2003) (Pubitemid 40075117)
13. Lu-Yao, G.L., Yao, S.L.: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349, 906-910 (1997) (Pubitemid 27139819)
14. Chirpaz, E., Colonna, M., Menegoz, F., Grosclaude, P., Schaffer, P., Arveux, P., Lesec'h, J.M., Exbrayat, C., Schaerer, R.: Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996. Int. J. Cancer 97, 372-376 (2002) (Pubitemid 34049030)
15. National Cancer Institute: Surveillance epidemiology and end results. http://seer.cancer.gov/faststats/sites.php?site=Prostate? Cancer&stat= Definitions (2008). Accessed 19 April 2008
16. Jones, J., Hunter, D.: Consensus methods for medical and health services research. BMJ 311, 376-380 (1995)
17. Agence Nationale d'Accréditation et d'Evaluation en Santé. Les traitements du cancer localiséde la prostate: synthèse. ANAES (2001)
18. Fédération Nationale des Centres de Lutte Contre le Cancer, Association Française d'Urologie. Standards, options et recommandations pour la prise en charge des patients atteints de cancer de la prostate non métastatique. Document de travail, FNCLCC (2001)
19. Detsky, A.S., Naglie, I.G.: A clinician's guide to cost-effectiveness analysis. Ann. Intern. Med. 113, 147-154 (1990) (Pubitemid 20218632)
20. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., Stoddart, G.L.: Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford University Press, Oxford (2005)
21. The Comprehensive R Archive Network: The R Project for Statistical Computing. http://www.r-project.org (2009). Accessed 9 April 2009
22. Remontet, L., Buemi, A., Velten, M., Jougla, E., Estève, J.: Evolution de l'incidence et de la mortalitépar cancer en France de 1978 à 2000. Institut de Veille Sanitaire, Paris (2002)
23. Hernàn, M.A., Hernàndez-Diaz, S., Werler, M.M., Mitchell, A.A.: Causal knowledge as a prerequisite for confounding evaluation: An application to birth defects epidemiology. Am. J. Epidemiol. 155, 176-184 (2002) (Pubitemid 34072741)
24. Soulié, M., Beuzeboc, P., Cornud, F., Eschwege, P., Gaschignard, N., Grosclaude, P., Hennequin, C., Maingon, P., Molinié, V., Mongiat-artus, P., Moreau, J.L., Paparel, P., Péneau, M., Peyromaure, M., Ravery, V., Rébillard, X., Richaud, P., Salomon, L., Staerman, F., Villers, A.: Recommandations de l'association française d'urologie: cancer de la prostate. Prog. Urol. 17, 1159-1230 (2007)
25. Andriole, G.L., Grubb III, R.L., Buys, S.S., Chia, D., Church, T.R., Fouad, M.N., Gelmann, E.P., Kvale, P.A., Reding, D.J., Weissfeld, J.L., Yokochi, L.A., Crawford, E.D., O'Brien, B., Clapp, J.D., Rathmell, J.M., Riley, T.L., Hayes, R.B., Kramer, B.S., Izmirlian, G., Miller, A.B., Pinsky, P.F., Prorok, P.C., Gohagan, J.K., Berg, C.D., PLCO Project Team: Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009)
26. Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L.J., Recker, F., Berenguer, A., Määttänen, L., Bangma, C.H., Aus, G., Villers, A., Rebillard, X., van der Kwast, T., Blijenberg, B.G., Moss, S.M., de Koning, H.J., Auvinen, A.: ERSPC Investigators.: Screening and prostatecancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009)
27. Haillot, O., Villers, A., Soulié, M., Baron, J.C.: Dépistage du cancer de la prostate (IV). Approche économique: les coûts des tests de dépistage et des traitements. Prog. Urol. 8, 517-523 (1998) (Pubitemid 128533947)
28. Neymark, N., Adriaenssen, I., Gorlia, T., Caleo, S., Bolla, M., Brochon, D.: Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur. J. Cancer 37, 1768-1774 (2001) (Pubitemid 32817051)
29. Amalric, F.: Analyse économique des coûts du cancer en France. Institut National du Cancer, Boulogne-Billancourt (2007)
30. Buron, C., Le Vu, B., Cosset, J.M., Pommier, P., Peiffert, D., Delannes, M., Flam, T., Guerif, S., Salem, N., Chauveinc, L., Livartowski, A.: Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. Int. J. Radiat. Oncol. Biol. Phys. 67, 812-822 (2007) (Pubitemid 46215887)
31. Bauvin, E., Soulié, M., Menegoz, F., Mace-Lesec'h, J., Buemi, A., Velten, M., Villers, A., Grosclaude, P.: Medical and non-medical determinants of prostate cancer management: a population-based study. Eur. J. Cancer 39, 2364-2371 (2003) (Pubitemid 37214861)
32. Max, W., Rice, D.P., Sung, H.Y., Michel, M., Breuer, W., Zhang, X.: The economic burden of prostate cancer, California, 1998. Cancer 94, 2906-2913 (2002) (Pubitemid 34547689)
33. Norlund, A., Alvegård, T., Lithman, T., Merlo, J., Noreen, D.: Prostate cancer. Prevalence-based healthcare costs. Scand. J. Urol. Nephrol. 37, 371-375 (2003) (Pubitemid 37463852)
34. Jayadevappa, R., Bloom, B.S., Chhatre, S., Fomberstein, K.M., Wein, A.J., Malkowicz, S.B.: Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer. J. Urol. 174, 1059-1064 (2005) (Pubitemid 41140680)
35. Penson, D.F., Chan, J.M., Urologic Diseases in America Project: Prostate cancer. J. Urol. 177, 2020-2029 (2007)
36. Wilson, L.S., Tesoro, R., Elkin, E.P., Sadetsky, N., Broering, J.M., Latini, D.M., DuChane, J., Mody, R.R., Carroll, P.R.: Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109, 518-527 (2007) (Pubitemid 46190959)
37. Chamberlain, J., Melia, J., Moss, S., Brown, J.: The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol. Assess. 1, 1-53 (1997)
38. Litwin, M.S., Pasta, D.J., Stoddard, M.L., Henning, J.M., Carroll, P.R.: Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993. J. Urol. 160, 445-448 (1998). (Pubitemid 29476695)
39. Erratum in: J. Urol. 160, 2164
40. Chang, S., Long, S.R., Kutikova, L., Bowman, L., Finley, D., Crown, W.H., Bennett, C.L.: Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J. Clin. Oncol. 22, 3524-3530 (2004) (Pubitemid 41109929)
41. Burkhardt, J.H., Litwin, M.S., Rose, C.M., Correa, R.J., Sunshine, J.H., Hogan, C., Hayman, J.A.: Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J. Clin. Oncol. 20, 2869-2875 (2002) (Pubitemid 34651516)
42. Grossfeld, G.D., Li, Y.P., Lubeck, D.P., Carroll, P.R.: Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology 60, 57-63 (2002) (Pubitemid 35304543)